Rigel Pharmaceuticals, Inc. (RIGL)

1,1000 0,0000 (0,00%) Alla chiusura: 04:00PM EDT

Rigel Pharmaceuticals, Inc.

611 Gateway Blvd
Suite 900
South San Francisco, CA 94080
United States
650 624 1100
https://www.rigel.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 147

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Raul R. Rodriguez	President, CEO & Director	1,17M	N/D	1961
Mr. Dean L. Schorno CPA	Executive VP & CFO	736,72k	N/D	1963
Mr. Raymond J. Furey J.D.	Executive VP, General Counsel & Corporate Secretary	683k	N/D	1968
Mr. David A. Santos	Executive VP & Chief Commercial Officer	737,18k	N/D	1963
Ms. Julie Patel	Senior VP of Human Resources	N/D	N/D	N/D
Dr. Esteban S. Masuda	Executive Vice President of Research	537,21k	N/D	1962
Mr. Joseph Lasaga	Executive VP & Chief Business Officer	N/D	N/D	1975
Dr. Lisa Rojkjaer M.D.	Executive VP & Chief Medical Officer	N/D	N/D	1966
Mr. Tarek Sallam	Vice President of Marketing	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Rigel Pharmaceuticals, Inc. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.